APTIOM Prescribing Information
APTIOM ® (eslicarbazepine acetate) Pivotal Publications
Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89(2-3):278-85.
http://www.ncbi.nlm.nih.gov/pubmed/20299189
Elger C, Halász P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-contolled, parallel-group phase III study. Epilepsia 2009;50:454-63.
http://www.ncbi.nlm.nih.gov/pubmed/19243424
Jacobson MP, Pazdera L, Bhatia P, Grinnell T, Chen H, Blum D, on behalf of the study 046 team. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. BMC Neurology. 2015;15:46. http://www.ncbi.nlm.nih.gov/pubmed/25880756
Sperling MR, Abou-Khalil B, Harvey J, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015;56(2):244-53.
http://www.ncbi.nlm.nih.gov/pubmed/25528898
Sperling MR, Harvey J, Grinnell T, Cheng H, Blum D. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: A randomized historical-control phase III study based in North America. Epilepsia. 2015;56(4):546-55. http://www.ncbi.nlm.nih.gov/pubmed/25689448
BROVANA Prescribing Information
Brovana® (arformoterol tartrate) Pivotal Publications
Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007;29(2):261-278.
http://www.ncbi.nlm.nih.gov/pubmed/17472819
Donohue JF, Hanania NA, Sciarappa KA, et al. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Resp Dis. 2008;2(2):37-48.
http://www.ncbi.nlm.nih.gov/pubmed/19124357
Hanania NA, Donahue JF, Nelson H, et al. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010;7(1):17-31.
http://www.ncbi.nlm.nih.gov/pubmed/20214460
Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008;5(1):25-34.
http://www.ncbi.nlm.nih.gov/pubmed/18259972
KYNMOBI Prescribing Information
Kynmobi™ (apomorphine hydrochloride) Sublingual Film Pivotal Publications
Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson’s Disease: A randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19:135-144.
http://www.ncbi.nlm.nih.gov/pubmed/31818699
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for use in patients with dementia-related psychosis.
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. LATUDA is not approved for use in patients under the age of 18 years.
LATUDA Prescribing Information
Latuda® (lurasidone HCl) Pivotal Publications
Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1-3):101-9.
http://www.ncbi.nlm.nih.gov/pubmed/23415311
Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160-8.
http://www.ncbi.nlm.nih.gov/pubmed/24170180
Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169-77.
http://www.ncbi.nlm.nih.gov/pubmed/24170221
Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957-67.
http://www.ncbi.nlm.nih.gov/pubmed/21676992
Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-36.
http://www.ncbi.nlm.nih.gov/pubmed/19497249
Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670-7.
http://www.ncbi.nlm.nih.gov/pubmed/23421963
Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6‑week, placebo‑controlled study. Psychopharmacol.ogy (Berl). 2013;225(3):519-30.
http://www.ncbi.nlm.nih.gov/pubmed/22903391
LONHALA MAGNAIR Prescribing Information
LONHALA MAGNAIR Patient Information
LONHALA MAGNAIR Instructions for Use
LONHALA® MAGNAIR® (glycopyrrolate) Pivotal Publications
Kerwin E, Donohue JF, Goodin T, Tosiello R, Wheeler A, Ferguson GT. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 3 and 4 randomized controlled trials [published online ahead of print July 19, 2017]. Respir Med.
https://doi.org/10.1016/j.rmed.2017.07.011
Ferguson GT, Goodin T, Tosiello R, Wheeler A, Kerwin E. Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study [published online ahead of print August 24, 2017]. Respir Med.
http://dx.doi.org/10.1016/j.rmed.2017.08.020
LUNESTA Prescribing Information
Lunesta® (eszopiclone) Pivotal Publications
Erman MK, Zammit G, Rubens R, et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med. 2008;4(3):229-34.
http://www.ncbi.nlm.nih.gov/pubmed/18595435
Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793-9.
http://www.ncbi.nlm.nih.gov/pubmed/14655910
McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin. 2006;22(9):1633-42.
http://www.ncbi.nlm.nih.gov/pubmed/16968566
Rosenberg R, Caron J, Roth T, Amato D. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med. 2005;6(1):15-22.
http://www.ncbi.nlm.nih.gov/pubmed/15680290
Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005;28(6):720-7.
http://www.ncbi.nlm.nih.gov/pubmed/16477959
Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20(12):1979-91.
http://www.ncbi.nlm.nih.gov/pubmed/15701215
XOPENEX HFA Prescribing Information
XOPENEX HFA Patient Information
Xopenex HFA® (levalbuterol tartrate) Pivotal Publications
Berger WE, Milgrom H, Skoner DP, et al. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. Curr Med Res Opin. 2006;22(6):1217-26.
http://www.ncbi.nlm.nih.gov/pubmed/16846555
SUNOVION and 
are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
LUNESTA,
, XOPENEX HFA, and BROVANA are registered trademarks of Sunovion Pharmaceuticals Inc.
APTIOM is a registered trademark of 
, used under license. LATUDA is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.
LONHALA and 
are registered trademarks of Sunovion Pharmaceuticals Inc. MAGNAIR is a registered trademark of PARI Pharma GmbH, used under license.
eFlow and eLete are registered trademarks of PARI Pharma GmbH.
KYNMOBI and 
are trademarks of Sunovion Pharmaceuticals Inc.
This site contains information intended for U.S. health care professionals only.
© 2020 Sunovion Pharmaceuticals Inc. All rights reserved.
Terms of Use | Privacy Notice and Cookie Notice | Contact Us | Submit a Medical Inquiry